Avalo Therapeutics targets 1H 2027 IND for long-acting anti-IL-1β antibody AVTX-010

Avalo Therapeutics Inc

Avalo Therapeutics Inc

AVTX

0.00
  • Avalo Therapeutics advanced AVTX-010, a long-acting next-generation anti-IL-1β antibody, to expand its inflammatory disease pipeline.
  • IND filing planned for the first half of 2027; first-in-human studies expected to follow.
  • No AVTX-010 clinical results were presented; the update focused on development timing.
  • Strategy targets less frequent dosing to support adherence in chronic disease, with initial focus on hidradenitis suppurativa.
  • Moves alongside recently reported positive Phase 2 topline results for lead drug abdakibart in hidradenitis suppurativa.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160700PRIMZONEFULLFEED9747403) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.